Intuit R&D increased by 0.5% to $840.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.8%, from $707.00M to $840.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 14.9% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $464.00M | $521.00M | $530.00M | $590.00M | $600.00M | $627.00M | $625.00M | $630.00M | $604.00M | $680.00M | $680.00M | $678.00M | $671.00M | $725.00M | $704.00M | $716.00M | $707.00M | $801.00M | $843.00M | $836.00M | $840.00M |
| QoQ Change | — | +12.3% | +1.7% | +11.3% | +1.7% | +4.5% | -0.3% | +0.8% | -4.1% | +12.6% | +0.0% | -0.3% | -1.0% | +8.0% | -2.9% | +1.7% | -1.3% | +13.3% | +5.2% | -0.8% | +0.5% |
| YoY Change | — | — | — | — | +29.3% | +20.3% | +17.9% | +6.8% | +0.7% | +8.5% | +8.8% | +7.6% | +11.1% | +6.6% | +3.5% | +5.6% | +5.4% | +10.5% | +19.7% | +16.8% | +18.8% |